



Important Dates

Meeting opens: December 10-14, 2021

Virtual platform available: December 8, 2021 at 9:00 AM ET

ASH News

Wendy Stock, MD, Anjali Seth Nayak Professor of Medicine, was elected to serve on the ASH Executive Committee as councilor. Read the announcement [here](#).

Second-year hematology/oncology fellow **Caner Saygin, MD**, was selected to receive an Abstract Achievement Award. He was also selected as one of 17 outstanding fellows to receive the 2021 ASH Research Training Award for Fellows (RTAF), a year-long program that aims to encourage careers in academic hematology by providing protected research time during training.

Undergraduate **Nicole Arellano** and graduate **Harrison Greenbaum**, who both work in the lab of Shannon Elf, PhD, were selected to receive Abstract Achievement Awards.

Juan Ibarra from Shannon Elf's lab received the ASH Minority Graduate Student Abstract Achievement Award.

Sessions, Presentations and Abstracts

*(Note that **bold names indicate UCCCC Members**, and underlined means affiliated with University of Chicago; Ordered chronologically)*

Friday, December 10, 2021

[Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy into Patient Care](#)

Result Type: Session

Program: Friday Satellite Symposia

Time and Location: Friday, December 10, 2021: 7:00 AM-10:00 AM; Centennial 2, Ballroom Level (Hyatt Regency Atlanta)

Speaker: **Peter A. Riedell, MD**

[Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice](#)

Result Type: Session

Program: Friday Satellite Symposia

Time and Location: Friday, December 10, 2021: 11:00 AM-2:00 PM; Atrium A (Atlanta Marriott Marquis)

Chair: **Michael R. Bishop, MD**

[Blood Buddies: Adult Clinical Malignant Hematology \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

#ASH21

Time and Location: Friday, December 10, 2021: 1:30 PM-2:00 PM; Balcony, Section 201 (Tabernacle)

Panelist: [Olatoyosi Odenike, MD](#)

[Blood Buddies: BMT Peds and Adult \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 1:30 PM-2:00 PM; Balcony, Section 203 (Tabernacle)

Panelist: [James LaBelle, MD, PhD](#)

[Blood Buddies: Pediatric Clinical Non-Malignant Hematology \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 1:30 PM-2:00 PM; Balcony, Section 206 (Tabernacle)

Panelist: [Jill de Jong, MD, PhD](#)

[Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure](#)

Result Type: Session

Program: Scientific Workshops

Time and Location: Friday, December 10, 2021: 2:00 PM-5:00 PM

Co-Chair and Moderator: [Lucy Godley, MD, PhD](#)

[The Role of Germline CHEK2 Variants in Hematologic Malignancies](#)

Result Type: Paper

Presenter: [Anase Asom](#)

Program: Scientific Workshops

Session: DNA Repair and Malignancy

Time and Location: Friday, December 10, 2021: 2:02 PM-2:46 PM; B211-B212 (Georgia World Congress Center)

[Q&A](#)

Result Type: Paper

Presenter: [Anase Asom](#)

Program: Scientific Workshops

Session: DNA Repair and Malignancy

Time and Location: Friday, December 10, 2021: 2:02 PM-2:46 PM; B211-B212 (Georgia World Congress Center)

Result Type: Paper

Number: N/A

Presenter: [Stephen Arnovitz](#)

Program: Scientific Workshops

Session: DNA Repair and Malignancy

Time and Location: Friday, December 10, 2021: 2:02 PM-2:46 PM; B211-B212 (Georgia World Congress Center)

[Live Q&A](#)

Result Type: Paper

Number: N/A

Presenter: [Stephen Arnovitz](#)

Program: Scientific Workshops

Session: DNA Repair and Malignancy

Time and Location:

Friday, December 10, 2021: 2:02 PM-2:46 PM

B211-B212 (Georgia World Congress Center)

#ASH21

[Blood Buddies: Adult Clinical Malignant Hematology \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 2:40 PM-3:10 PM;
Balcony, Section 201 (Tabernacle)

Panelist: [Olatoyosi Odenike, MD](#)

[Blood Buddies: Pediatric Clinical Non-Malignant Hematology \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 2:40 PM-3:10 PM; Balcony, Section 206 (Tabernacle)

Panelist: [Jill de Jong, MD, PhD](#)

[Use of a Modified-Delphi Approach to Define the Pleiotropic GATA2-Deficient Phenotype for the Development of Acmg-AMP GATA2 Variant Curation Rules](#)

Presenter: [Taylor Walker](#)

Program: Scientific Workshops

Session: Variant Interpretation and Disease Modeling - Quick Fire Talks

Time and Location: Friday, December 10, 2021: 2:47 PM-3:16 PM; B211-B212 (Georgia World Congress Center)

[Blood Buddies: BMT Peds and Adult \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 2:40 PM-3:10 PM; Balcony, Section 203 (Tabernacle)

Panelist: [James LaBelle, MD, PhD](#)

[Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience](#)

Result Type: Session

Program: Friday Satellite Symposia

Time and Location: Friday, December 10, 2021: 3:00 PM-6:00 PM; Atrium B (Atlanta Marriott Marquis)

Chair: [Wendy Stock, MD](#)

[Clinical Trial Challenges: From the Bench to the Patient](#)

Result Type: Session

Program: Scientific Workshops

Time and Location: Friday, December 10, 2021: 3:11 PM-4:01 PM; B216-B217 (Georgia World Congress Center)

Moderator: [Sonali M. Smith, MD](#)

[Blood Buddies: BMT Peds and Adult \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 4:35 PM-5:00 PM; Balcony, Section 203 (Tabernacle)

Panelist: [James LaBelle, MD, PhD](#)

[Blood Buddies: Pediatric Clinical Non-Malignant Hematology \(in-person\)](#)

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 4:35 PM-5:00 PM; Balcony, Section 206 (Tabernacle)

Panelist: [Jill de Jong, MD, PhD](#)

[Blood Buddies: Adult Clinical Malignant Hematology \(in-person\)](#)

#ASH21

Result Type: Session

Program: Trainee Activities and Services

Time and Location: Friday, December 10, 2021: 4:35 PM-5:00 PM; Balcony, Section 201 (Tabernacle)

Panelist: [Olatoyosi Odenike, MD](#)

[Bridging Clinical Gaps in B-Cell Lymphomas: Linking Novel Mechanisms to Advance New Treatment Strategies](#)

Result Type: Session

Program: Friday Satellite Symposia

Time and Location: Friday, December 10, 2021: 7:00 PM-10:00 PM; VIRTUAL PROGRAM

Speakers: [Sonali M. Smith, MD](#)

Saturday, December 11, 2021

[Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols](#)

Result Type: Paper

Number: 111

Presenter: Andrew Hantel

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Myeloid Malignancies

Time and Location: Saturday, December 11, 2021: 9:30 AM-11:00 AM; B207-B208 (Georgia World Congress Center)

A Hantel...[Wendy Stock, MD](#)...G Abel

[Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study](#)

Result Type: Paper

Number: 66

Presenter: Guillermo Garcia-Manero

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment

Time and Location: Saturday, December 11, 2021: 9:30 AM-11:00 AM; B401-B402 (Georgia World Congress Center)

G Garcia-Manero...[Olatoyosi Odenike, MD](#)...M Savona

[Whole-Genome CRISPR Screening Identifies N-Glycosylation As an Essential Pathway and a Potential Novel Therapeutic Target in CALR-Mutant MPN](#)

Result Type: Paper

Number: 58

Presenter: Anna Marneth

Program: Oral and Poster Abstracts

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational I

Time and Location: Saturday, December 11, 2021: 9:30 AM-11:00 AM; Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)

A Marneth....[Shannon Elf, PhD](#)...A Mullaly

[Daratumumab \(DARA\) Plus Lenalidomide, Bortezomib, and Dexamethasone \(RVd\) in Patients \(Pts\) with Transplant-Eligible Newly Diagnosed Multiple Myeloma \(NDMM\): Updated Analysis of Griffin after 24 Months of Maintenance](#)

Result Type: Paper

Number: 79

#ASH21

Presenter: Jacob Laubach

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Pro prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Time and Location: Saturday, December 11, 2021: 9:30 AM-11:00 AM; Hall C1 (Georgia World Congress Center)
J Laubach...[Andrzej Jakubowiak, MD, PhD](#)...P Voorhees

[IL13 Contributes to Fibrotic Progression of the Myeloproliferative Neoplasms](#)

Result Type: Paper

Number: 60

Presenter: Johanna Melo-Cardenas

Program: Oral and Poster Abstracts

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational I

Time and Location: Saturday, December 11, 2021: 9:30 AM-11:00 AM; Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)

J Melo-Cardenas...[Sandeep Gurbuxani, MBBS, PhD](#)...J Crispino

[Definitions of Structural Racism](#)

Result Type: Session

Program: Anti-Racism Studio

Time and Location:

Saturday, December 11, 2021: 11:00 AM-11:30 AM

BC Hall - ASH Anti-Racism Studio (Georgia World Congress Center) Sunday, December 12, 2021: 6:30 PM-7:00 PM

BC Hall - ASH Anti-Racism Studio (Georgia World Congress Center)

Panelist: [Monica Vela, MD, FACP](#)

[Efficacy of Tisagenlecleucel in Adult Patients \(Pts\) with High-Risk Relapsed/Refractory Follicular Lymphoma \(r/r FL\): Subgroup Analysis of the Phase II Elara Study](#)

Result Type: Paper

Number: 131

Presenter: Catherine Thieblemont

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas

Time and Location: Saturday, December 11, 2021: 12:00 PM-1:30 PM; Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)

C Thieblemont...[Peter A. Riedell, MD](#)...M Dreyling

[Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine](#)

Result Type: Paper

Number: 241

Presenter: Jacqueline Garcia

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome

Time and Location: Saturday, December 11, 2021: 2:00 PM-3:30 PM; B207-B208 (Georgia World Congress Center)

J Garcia...[Olatoyosi Odenike, MD](#)...G Garcia-Manero

[The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies](#)

Result Type: Paper

Number: 253

#ASH21

Presenter: Melody Smith

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets

Time and Location: Saturday, December 11, 2021: 2:00 PM-3:30 PM; Hall A1 (Georgia World Congress Center)
M Smith...[Eric R Littmann, BA](#)...[A Facciabene](#)

[High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults \(AYAs\) with Acute Myeloid Leukemia \(AML\) \(Alliance\)](#)

Result Type: Paper

Number: 221

Presenter: Karilyn Larkin

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical and Epidemiological: COVID and beyond

Time and Location: Saturday, December 11, 2021: 2:00 PM-3:30 PM; B308-B309 (Georgia World Congress Center)
K Larkin...[Richard A. Larson, MD](#)...[A Eisfeld](#)

[Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia \(AML\) Patients \(Pts\) after Frontline Treatment with Intensive Induction Chemotherapy \(IC\), Targeted Inhibitors, or Hypomethylating Agents \(HMA\) \(Alliance\)](#)

Result Type: Paper

Number: 226

Presenter: Alice Mims

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Response Prediction across the Spectrum of DNA, RNA, Protein and Ex Vivo Cells

Time and Location: Saturday, December 11, 2021: 2:00 PM-3:30 PM; Sidney Marcus Auditorium (Georgia World Congress Center)
U Borate...[Richard A. Larson, MD](#)...[A Eisfeld](#)

[Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation](#)

Result Type: Paper

Number: 320

Presenter: Simone Feurstein

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational: Genomics and Novel Targets in MDS

Time and Location: Saturday, December 11, 2021: 4:00 PM-5:30 PM; B211-B212 (Georgia World Congress Center)
[Simone Feurstein](#)... [Michael W. Drazer, MD](#)...[Wendy Stock, MD](#)

[Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 \(Alliance\) Cohort with U.S. Population-Level Data](#)

Result Type: Paper

Number: 337

Presenter: Lori Muffly

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research-Lymphoid Malignancies: Disparities in Patient Care and Outcomes

Time and Location: Saturday, December 11, 2021: 4:00 PM-5:30 PM; B207-B208 (Georgia World Congress Center)
L Muffly...[Richard A. Larson, MD](#)...[Wendy Stock, MD](#)

[Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma](#)

#ASH21

Result Type: Paper

Number: 330

Presenter: Romanos Sklavenitis-Pistofidis

Program: Oral and Poster Abstracts

Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Immunology

Time and Location: Saturday, December 11, 2021: 4:00 PM-5:30 PM; Hall A1 (Georgia World Congress Center)

R Sklavenitis-Pistofidis...[Andrzej Jakubowiak, MD, PhD](#)...I Ghobrial

[Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an *IDH1* or *IDH2* Mutation](#)

Result Type: Paper

Number: 1276

Presenter: Eytan Stein

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)

E Stein...[Olatoyosi Odenike, MD](#)...M Tallman

[Entospletinib \(ENTO\) and Decitabine \(DEC\) Combination Therapy in Older Newly Diagnosed \(ND\) Acute Myeloid Leukemia \(AML\) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial](#)

Result Type: Paper

Number: 1279

Presenter: Vu Duong

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)

V Duong...[Wendy Stock, MD](#)...M Boyiadzis

[Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 \(NCT00005089, NCT00070018, NCT01359592\)](#)

Result Type: Paper

Number: 1423

Presenter: Deborah Stephens

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)

D Stephens...[Sonali M. Smith, MD](#)...Dan Persky

[A Phase 1 Study Evaluating ASTX727 \(decitabine and cedazuridine\) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy](#)

Result Type: Paper

Number: 1245

Presenter: Gabriel Mannis

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)

G Mannis...[Olatoyosi Odenike, MD](#)...C DiNardo

#ASH21

[Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory \(R/R\) CD22+ B-Cell Acute Lymphoblastic Leukemia \(B-ALL\)](#)

Result Type: Paper

Number: 1746

Presenter: Nitin Jain

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
N Jain...[Hongtao Liu, MD, PhD](#)...[Richard Larson, MD](#)

[A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma \(ReCORD-FL\)](#)

Result Type: Paper

Number: 1349

Presenter: Gilles Salles

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
G Salles...[Sonali M. Smith, MD](#)...B Link

[5hmC Gene Signature Predicts the Treatment Response to Azacitidine with High-Dose Cytarabine and Mitoxantrone in AML](#)

Result Type: Paper

Number: 1305

Presenter: [Kirk Cahill](#)

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
[Kirk Cahill](#), [Noreen Fulton](#), [Wendy Stock, MD](#), [Olatoyosi Odenike, MD](#), [Chuan He, PhD](#), D Han

[CUX1 Deficiency Potentiates RAS Signaling to Drive Malignancy](#)

Result Type: Paper

Number: 1159

Presenter: [Megan McNerney, MD, PhD](#)

Program: Oral and Poster Abstracts

Session: 603. Oncogenes and Tumor Suppressors: Basic: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
[Ningfei An, PhD](#), [Molly K Imgruet, PhD](#), [Saira Khan, MS](#), [Lia Jueng, BA](#), [Sandeep Gurbuxani, MBBS, PhD](#) and [Megan E. McNerney, MD, PhD](#)

[Food Insecurity, Quality of Life, Healthcare Utilization, and Clinical Disease Outcomes in AYA Patients with Sickle Cell Disease](#)

Result Type: Paper

Number: 972

Presenter: [Sharjeel Syed](#)

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM, Hall B5 (Georgia World Congress Center)
[Sharjeel Syed, MD](#), [Kristen Wroblewski, MS](#), [Radhika Peddinti, MD](#), [Gabrielle Lapping-Carr, MD](#) and [Wendy S Darlington, MD, MAPP](#)

#ASH21

[Gilteritinib \(GILT\) Monotherapy with Addition of Decitabine \(DEC\) in Non-Responders in Older Newly Diagnosed \(ND\) FLT3 Mutated Acute Myeloid Leukemia \(AML\) Patients Having High and Low Variant Allele Frequency \(VAF\): A Phase 2/1b Sub-Study of the Beat AML Master Trial](#)

Result Type: Paper

Number: 1277

Presenter: Elie Traer

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
E Traer...[Wendy Stock, MD](#)...U Borate

[A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia](#)

Result Type: Paper

Number: 1282

Presenter: John Byrd

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
J Byrd...[Wendy Stock, MD](#)

[Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib \(80 mg Once Daily\) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase](#)

Result Type: Paper

Number: 1478

Presenter: Jorge Cortes

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Time and Location: Saturday, December 11, 2021: 5:30 PM-7:30 PM; Hall B5 (Georgia World Congress Center)
J Cortes...[Richard A. Larson, MD](#)...T Hughes

Sunday, December 12, 2021

[Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory \(R/R\) Aggressive B-Cell Non-Hodgkin's Lymphoma \(aBNHL\) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research \(CIBMTR\) Registry](#)

Result Type: Paper

Number: 429

Presenter: Daniel Landsburg

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research-Lymphoid Malignancies: Transplant and Cellular Therapy

Time and Location: Sunday, December 12, 2021: 9:30 AM-11:00 AM; B308-B309 (Georgia World Congress Center)
D Landsburg...[Peter A. Riedell, MD](#)...C Turtle

[614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies I](#)

Result Type: Session

Program: Oral and Poster Abstracts

#ASH21

Time and Location:

Sunday, December 12, 2021: 9:30 AM-11:00 AM; B211-B212 (Georgia World Congress Center)

Moderator: [Jennifer McNeer, MD](#)

[Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN \(E2906\) Clinical Study](#)

Result Type: Paper

Number: 413

Presenter: Yishai Ofran

Program: Oral and Poster Abstracts

Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence

Time and Location: Sunday, December 12, 2021: 9:30 AM-11:00 AM; B304-B305 (Georgia World Congress Center)

Y Ofran...[Daniel Arber, MD](#)...M Llitzow

[Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma \(DLBCL\) Immune Environments and Identifies Associations with Specific Oncogenic Alterations](#)

Result Type: Paper

Number: 449

Presenter: Sravya Tumuluru

Program: Oral and Poster Abstracts

Session: 622. Lymphomas: Translational–Non-Genetic: Lymphoma biology and microenvironment

Time and Location: Sunday, December 12, 2021: 12:00 PM-1:30 PM; C108-C109 (Georgia World Congress Center)

Sravya Tumuluru...[Jovian Yu, MD](#), [Alan Cooper](#), [Xiufen Chen, PhD](#), [Sonali M. Smith, MD](#)...[Justin Kline, MD](#)

[Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleuce \(Axi-Cel\) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma](#)

Result Type: Paper

Number: 2

Presenter: Frederick Locke

Program: General Sessions

Session: Plenary Scientific Session

Time and Location: Sunday, December 12, 2021: 2:00 PM-4:00 PM; Hall C2-C3 (Georgia World Congress Center)

F Locke...[Peter A. Riedell, MD](#)...J Westin

[Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome](#)

Result Type: Paper

Number: 537

Presenter: Amer Zeidan

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High-Risk and

Relapsed/Refractory Myelodysplastic Syndrome

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; B211-B212 (Georgia World Congress Center)

A Zeidan...[Olatoyosi Odenike, MD](#)...G Garcia-Manero

[Updated Results from CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleuce, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma](#)

Result Type: Paper

Number: 549

Presenter: Thomas Martin

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Cellular Therapies for Myeloma

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; Hall C2-C3 (Georgia World Congress Center)

T Martin...[Andrzej Jakubowiak, MD, PhD](#)...S Jagannath

#ASH21

[Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma](#)

Result Type: Paper

Number: 548

Presenter: Noopur Rajeev

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Cellular Therapies for Myeloma

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; Hall C2-C3 (Georgia World Congress Center)
N Rajeev...[Andrzej Jakubowiak, MD, PhD](#)...M Alsina

[Ciltacabtagene Autoleuclel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study](#)

Result Type: Paper

Number: 550

Presenter: Maria-Victoria Mateos

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Cellular Therapies for Myeloma

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; Hall C2-C3 (Georgia World Congress Center)
M Mateos...[Andrzej Jakubowiak, MD, PhD](#)...H Einsele

[The KDM5 Family of Histone Lysine Demethylases Are Targets of R-2-Hydroxyglutarate in IDH Mutant Tumors](#)

Result Type: Paper

Number: 503

Presenter: Kathryn Gunn

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: New mechanisms of epigenetic dysregulation in hematologic cancers

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; B302-B303 (Georgia World Congress Center)
K Gunn...[John Cao](#)...[Lucy A. Godley, MD, PhD](#)...JA Losman

[721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities; Novel Conditioning Approaches.](#)

Result Type: Session

Program: Oral and Poster Abstracts

Time and Location: Sunday, December 12, 2021: 4:30 PM-6:00 PM; B308-B309 (Georgia World Congress Center)

Moderator: [James LaBelle, MD, PhD](#)

[Asparaginase Induced Liver Enzyme Elevation Is More Prevalent in Hispanics Children with ALL and in Patients with SOD2 rs4880 CC Genotype](#)

Result Type: Paper

Number: 2279

Presenter: Amani Alqahatni

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
S Wu...[Wendy Stock, MD](#)...H Alachkar

[A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma](#)

Result Type: Paper

Number: 2420

Presenter: [Kirk Cahill](#)

#ASH21

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

Kirk Cahill, MD...[Theodore G. Karrison, PhD](#), [Jessica Robertson, CCRP](#), [Justin Kline, MD](#) and [Sonali M. Smith, MD](#)

[A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma](#)

Result Type: Paper

Number: 2759

Presenter: [Ben Derman, MD](#)

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Ben A Derman, MD](#), [Ajay Major, MD, MBA](#)...[Murtuza M. Rampurwala, MD, MPH](#), [Luis Alcantar, Bernadette M. Libao](#), [Amanda McIver](#), [Evangelia Andreatos](#), [Sarah Major](#), [Brittany Wolfe](#), [Martha Gorski](#), [Theodore G. Karrison, PhD](#), [Andrew Stefka, MS](#) and [Andrzej Jakubowiak, MD, PhD](#)

[Addressing Sickle Cell Disease Implicit Bias in Internal Medicine Residents](#)

Result Type: Paper

Number: 2965

Presenter: [Nabil Abou Baker, MD](#)

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Nabil Abou Baker, MD](#), [Daniela Anderson, MD](#) and [Byron Brooks, PhD](#)

[Rapid Analysis and Prediction of Drug Resistance in Leukemia By Novel Nascent RNA-Driven Flow Imaging Technologies and Biomarkers](#)

Result Type: Paper

Number: 2242

Presenter: [Shaun Wood](#)

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Shaun Wood](#), [Amber Willbanks](#) and [Jason Xiaojun Cheng, MD, PhD](#)

[A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucl and Tisagenlecleucl for Relapsed/Refractory Aggressive B-Cell Lymphomas](#)

Result Type: Paper

Number: 2512

Presenter: [Peter Riedell, MD](#)

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Peter A. Riedell, MD](#)...[Michael R. Bishop, MD](#) and D Porter

[Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium](#)

Result Type: Paper

Number: 2843

Presenter: [Kitsada Wudhikarn](#)

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster II

#ASH21

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
K Wudhikarn...[Peter A. Riedell, MD](#), MA Perales

[Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone \(D-RVd\) in Transplant-Eligible Newly Diagnosed Multiple Myeloma \(NDMM\) Patients \(Pts\): A Subgroup Analysis of Griffin](#)

Result Type: Paper

Number: 2723

Presenter: Larry Anderson

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
L Anderson...[Andrzej Jakubowiak, MD, PhD](#)...P Richardson

[Stem Cell Collection with Daratumumab \(DARA\)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma \(NDMM\) Patients \(pts\) in the Griffin and Master Studies](#)

Result Type: Paper

Number: 2852

Presenter: Saurabh Chhabra

Program: Oral and Poster Abstracts

Session: 711. Cell Collection and Processing: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
S Chhabra...[Andrzej Jakubowiak, MD, PhD](#)...P Voorhees

[Results from a Global Randomized Phase 3 Study of Guadecitabine \(G\) Vs Treatment Choice \(TC\) in 302 Patients with Relapsed or Refractory \(r/r\) Acute Myeloid Leukemia after Intensive Chemotherapy \(ASTRAL-2 Study\)](#)

Result Type: Paper

Number: 2344

Presenter: Gail Roboz

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
G Roboz...[Wendy Stock, MD](#)...H Dohner

[Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib \(ALXN2075\) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma](#)

Result Type: Paper

Number: 2423

Presenter: Paul Hamlin

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
P Hamlin...[Sonali M. Smith, MD](#)...S Smith

[Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma \(NCT#03269669\): SWOG S1608](#)

Result Type: Paper

Number: 2425

Presenter: Paul Barr

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
P Barr...[Sonali M. Smith, MD](#)...J Friedberg

#ASH21

[Chromatin Accessibility Landscapes of Acute Lymphoblastic Leukemia](#)

Result Type: Paper

Number: 2215

Presenter: Kelly Barnett

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

K Barnett...[Wendy Stock, MD](#)...D Savic

[Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?](#)

Result Type: Paper

Number: 2746

Presenter: Rakesh Popat

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

R Popat...[Asim V. Farooq, MD](#)...E Terpos

[First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies \(CLBR001 + SWI019\)](#)

Result Type: Paper

Number: 2822

Presenter: Liana Nikolaenko

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster II

Time and Location: Sunday, December 12, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

L Nikolaenko...[Peter A. Riedell, MD](#)...T Young

[Definitions of Structural Racism](#)

Result Type: Session

Program: Anti-Racism Studio

Time and Location:

Sunday, December 12, 2021: 6:30 PM-7:00 PM; BC Hall - ASH Anti-Racism Studio (Georgia World Congress Center)

Panelist: [Monica Vela, MD, FACP](#)

Monday, December 13, 2021

[Type 1 Calreticulin Mutations Differentially Activate the IRE1 \$\alpha\$ -XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms](#)

Result Type: Paper

Number: 628

Presenter: [Juan Ibarra](#)

Program: Oral and Poster Abstracts

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational II

Time and Location:

Monday, December 13, 2021: 10:30 AM-12:00 PM

B211-B212 (Georgia World Congress Center)

[Juan Ibarra](#), [Yassmin Elbanna](#), [Katarzyna Kurylowicz](#), [Harrison S Greenbaum](#), [Maria Evers](#), [Nicole S Arellano](#), [Dongbo Yang](#), [Althea Bock-Hughes](#), [Chenyu Liu](#), [Quinn Smith](#), [Julian Lutze](#), [Julian Baumeister](#), [Benjamin Nicholson](#),

#ASH21

Diane Silva, Luke Maxwell, Jonathan Dowgielewicz, Michele Ciboddo, MD...Sandeep Gurbuxani, MBBS, PhD...Scott Oakes, MD and Shannon Elf, PhD

Treatment landscape for Treatment of Relapsed/Refractory Adult Acute Lymphoblastic Leukemia - Clinical Discussant

Result Type: Paper

Number: N/A

Presenter: [Richard Larson, MD](#)

Program: Special-Interest Sessions

Session: ASH-FDA Joint Symposium on Newly Approved Drugs: Treatment Landscape in the Era of Novel Therapies

Time and Location: Monday, December 13, 2021: 10:30 AM-12:00 PM; Hall C2-C3 (Georgia World Congress Center)

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Result Type: Paper

Number: 639

Presenter: Jennifer Woyach

Program: Oral and Poster Abstracts

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological II

Time and Location: Monday, December 13, 2021: 10:30 AM-12:00 PM; Thomas Murphy Ballroom 3-4 (Georgia World Congress Center)

J Woyach...[Richard A. Larson, MD](#)...J Byrd

Expanding the Treatment Landscape for Follicular Lymphomas – Clinical Discussant

Result Type: Paper

Number: N/A

Presenter: [Sonali Smith, MD](#)

Program: Special-Interest Sessions

Session: ASH-FDA Joint Symposium on Newly Approved Drugs: Treatment Landscape in the Era of Novel Therapies

Time and Location: Monday, December 13, 2021: 10:30 AM-12:00 PM; Hall C2-C3 (Georgia World Congress Center)

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Result Type: Paper

Number: 622

Presenter: Steven Horwitz

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy

Time and Location: Monday, December 13, 2021: 10:30 AM-12:00 PM; Hall A1 (Georgia World Congress Center)

S Horwitz...[Sonali M. Smith, MD](#)

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleuceel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Result Type: Paper

Number: 739

Presenter: Sattva Neelapu

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Cellular Therapies for Low and High Grade Lymphomas

Time and Location: Monday, December 13, 2021: 2:45 PM-4:15 PM; A411-A412 (Georgia World Congress Center)

S Neelapu...[Peter A. Riedell, MD](#)...J Chavez

#ASH21

[Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia \(AML\) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes](#)

Result Type: Paper

Number: 685

Presenter: Karilyn Larkin

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical and Epidemiological: Outcomes and Omics Potpourri

Time and Location: Monday, December 13, 2021: 2:45 PM-4:15 PM; Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)

M Cusan...[Richard A. Larson, MD](#)...AK Eisfeld

[622. Lymphomas: Translational–Non-Genetic: Lymphoma biology](#)

Result Type: Session

Program: Oral and Poster Abstracts

Time and Location: Monday, December 13, 2021: 2:45 PM-4:15 PM; Hall A1 (Georgia World Congress Center)

Moderator: [Justin Kline, MD](#)

[Safety and Efficacy of Menin Inhibition in Patients \(Pts\) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase \(Ph\) 1, First-in-Human Study of SNDX-5613 \(AUGMENT 101\)](#)

Result Type: Paper

Number: 699

Presenter: Eytan Stein

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Targeted Therapies and Novel Therapies

Time and Location: Monday, December 13, 2021: 2:45 PM-4:15 PM; Georgia Ballroom 1-3 (Georgia World Congress Center)

EM Stein...[Michael Thirman, MD](#)...GC Issa

[Structural and Social Barriers to Survival in Adolescent and Young Adult \(AYA\) Patients with Acute Myeloid Leukemia \(AML\)](#)

Result Type: Paper

Number: 844

Presenter: Madelyn Burkart

Program: Oral and Poster Abstracts

Session: 906. Outcomes Research—Myeloid Malignancies: Health Equity and Disparities

Time and Location: Monday, December 13, 2021: 4:30 PM-6:00 PM; B211-B212 (Georgia World Congress Center)

Ivy Abraham, MD...[Anand Ashwin Patel, MD](#)...[Wendy Stock, MD](#)...S Dinner

[Age-Related Clonal Hematopoiesis Is a Precursor for Adult Acute Lymphoblastic Leukemia](#)

Result Type: Paper

Number: 3477

Presenter: [Caner Saygin, MD](#)

Program: Oral and Poster Abstracts

Session: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Caner Saygin, MD](#)...[Alexandra E Rojek, MD](#), [Peng Wang, MD](#), [Jeremy Segal, MD](#), [Wendy Stock, MD](#) and [BD Shah](#)

[Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data](#)

Result Type: Paper

Number: 4013

#ASH21

Presenter: [Ajay Major, MD, MBA](#)

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Lymphoid Malignancies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Ajay Major, MD, MBA](#), [Rachel C Wright](#), [Sonal M. Smith, MD](#) and [Elbert S Huang, MD, MPH](#)

[Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma](#)

Result Type: Paper

Number: 4116

Presenter: Lucia Notardonato

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

LD Notardonato, [Spencer Langerman](#)...[Brian Chiu, PhD](#) and [Ben A. Derman, MD](#)

[Adverse Childhood Experiences \(ACEs\) in Newly-Diagnosed Childhood and Adolescent/Young Adult \(AYA\) Cancer Patients with Hematologic Malignancies](#)

Result Type: Paper

Number: 4108

Presenter: [Lindsay Schwartz, MD](#)

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Lindsay F Schwartz, MD](#), [Marcia M Tan, PhD](#), [Julie S McCrae, PhD](#), [Tiffany Burkhardt, PhD](#)...[Tara O Henderson, MD, MPH](#)

[Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma](#)

Result Type: Paper

Number: 3832

Presenter: Matthew Frigault

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

MJ Frigault...[Andrzej Jakubowiak, MD, PhD](#) and [Michael R. Bishop, MD](#)

[Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database](#)

Result Type: Paper

Number: 4121

Presenter: Gregory Calip

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

GS Calip... [Brian Chiu, PhD](#)...N Neparidze

[Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma](#)

Result Type: Paper

Number: 3789

Presenter: [Ben Derman, MD](#)

Program: Oral and Poster Abstracts

Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster III

#ASH21

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
Ben A Derman, MD, [Spencer S Langerman](#), [Andrzej Jakubowiak, MD, PhD](#) and [Brian Chiu, PhD](#)

[Myeloproliferative Neoplasm-Associated Type 2 Calreticulin Mutations Differentially Activate and Depend on the ATF6 Pathway of the UPR](#)

Result Type: Paper

Number: 3588

Presenter: [Nicole Arellano](#)

Program: Oral and Poster Abstracts

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM

Hall B5 (Georgia World Congress Center)

[Nicole S Arellano](#), [Katarzyna Kurylowicz](#), [Luke Maxwell](#), [Harrison S Greenbaum](#), [Juan Ibarra](#) and [Shannon Elf, PhD](#)

[Type I Calreticulin Mutations Result in Hyperactivation of Its Acetyltransferase Function and Iron Metabolism, Inducing a Susceptibility to Ferroptosis](#)

Result Type: Paper

Number: 3593

Presenter: [Harrison Greenbaum](#)

Program: Oral and Poster Abstracts

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Harrison S Greenbaum](#), [Maria Evers](#), [Alex Rosencrance](#), [Luke Maxwell](#), [Katarzyna Kurylowicz](#), [Nicole S Arellano](#),

[Michele Ciboddo, MD](#), [Jinjun Gao](#), [Juan Ibarra](#) and [Shannon Elf, PhD](#)

[A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732](#)

Result Type: Paper

Number: 3398

Presenter: [Jennifer McNeer, MD](#)

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular

Immunotherapies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Jennifer L. McNeer, MD](#)...[ML Loh](#)

[Phase I and Expansion Study of Eprenetapopt \(APR-246\) in Combination with Venetoclax \(VEN\) and Azacitidine \(AZA\) in TP53-Mutant Acute Myeloid Leukemia \(AML\)](#)

Result Type: Paper

Number: 3409

Presenter: [Guillermo Garcia-Manero](#)

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular

Immunotherapies: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[G Garcia-Manero](#)...[Olatoyosi Odenike, MD](#)...[DA Sallman](#)

[Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma](#)

Result Type: Paper

Number: 3528

Presenter: [Gilles Salles](#)

Program: Oral and Poster Abstracts

#ASH21

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
G Salles...[Sonali M. Smith, MD](#)...B Link

[Efficacy and Safety of Ciltacabtagene Autoleucl in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis](#)

Result Type: Paper

Number: 3938

Presenter: [Andrzej Jakubowiak, MD, PhD](#)

Program: Oral and Poster Abstracts

Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

[Andrzej Jakubowiak, MD, PhD](#)...S Jagannath

[Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma \(CHARIOT Trial\)](#)

Result Type: Paper

Number: 3847

Presenter: Sairah Ahmed

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

S Ahmed...[Peter A. Riedell, MD](#)...HE Heslop

[Ivosidenib \(IVO\) in Combination with Azacitidine \(AZA\) in Newly Diagnosed \(ND\) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia \(AML\) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial](#)

Result Type: Paper

Number: 875

Presenter: Prapti Patel

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Updates in treatment for high-risk AML

Time and Location: Monday, December 13, 2021: 6:15 PM-7:45 PM; Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)

P Patel...[Wendy Stock, MD](#)...AS Mims

[S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine \(CC-486\) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements](#)

Result Type: Paper

Number: 3565

Presenter: Elizabeth Brem

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

EA Brem...[Sonali M. Smith, MD](#)

[Efficacy of Oral Decitabine/Cedazuridine \(ASTX727\) in the CMML Subgroup from the Ascertain Phase 3 Study](#)

Result Type: Paper

Number: 3682

Presenter: Michael Savona

#ASH21

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes — Clinical and Epidemiological: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
M Savona...[Olatoyosi Odenike, MD](#)...G Garcia-Manero

[Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia](#)

Result Type: Paper

Number: 3304

Presenter: Daniel Ferguson

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
D Ferguson...[Wendy Stock, MD](#)...D Savic

[Spacing Constraints of Neighboring Zinc Finger Modules within GATA2](#)

Result Type: Paper

Number: 3306

Presenter: Mabel Jung

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
MM Jung...[Lucy A. Godley, MD, PhD](#) and EH Bresnick

[A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients \(\$\geq 70\$ Years of Age\) with Chronic Lymphocytic Leukemia \(CLL\)](#)

Result Type: Paper

Number: 3728

Presenter: Jennifer Woyach

Program: Oral and Poster Abstracts

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
JA Woyach...[Diane Feldman](#)...J Byrd

[Myeloid-Biased HSC Require Semaphorin4a from the Bone Marrow Niche for Self-Renewal Under Stress and Life-Long Persistence](#)

Result Type: Paper

Number: 3283

Presenter: Dorsa Toghani

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis, Aging and Inflammation: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
D Toghani...[Sharon Zeng](#)...L Silberstein

[White Blood Cell Count \(WBC\) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia \(AML\) Patients \(Pts\) \(Alliance\)](#)

Result Type: Paper

Number: 3369

Presenter: Michael Ozga

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)
MP Ozga...[Richard A. Larson, MD](#)...AS Mims

#ASH21

[A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer \(CAR NK\) Cell Therapy, in Subjects with B-Cell Malignancies](#)

Result Type: Paper

Number: 3868

Presenter: Michael Dickinson

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Time and Location: Monday, December 13, 2021: 6:00 PM-8:00 PM; Hall B5 (Georgia World Congress Center)

M Dickinson...[Hongtao Liu, MD, PhD](#)...BT Hill

[Elranatamab \(PF-06863135\), a B-Cell Maturation Antigen \(BCMA\) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetism-1](#)

Result Type: Paper

Number: 895

Presenter: Michael Sebag

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

Time and Location: Monday, December 13, 2021: 6:15 PM-7:45 PM; A411-A412 (Georgia World Congress Center)

M Sebag... [Andrzej Jakubowiak, MD, PhD](#)...A Lesokhin

Tuesday, December 14, 2021

[Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study](#)

Result Type: Paper

Number: LBA-6

Presenter: [Michael Bishop, MD](#)

Program: General Sessions

Session: Late-Breaking Abstracts Session

Time and Location: Tuesday, December 14, 2021: 9:00 AM-10:30 AM; Hall C2-C3 (Georgia World Congress Center)

[Michael Bishop, MD](#)...JR Westin